Koneksa contributed to the new Digital Medicine Society (DiMe) V3+ framework, which adds usability to the process of validating digital health technologies (DHTs). Usability is an important aspect of successful…
Read More
The recent Alzheimer’s and Parkinson’s Disease Conference (ADPD) demonstrated that it is an exciting time for drug development in Parkinson’s disease. Parkinson’s disease is being redefined by alpha synuclein biology,…
“Rare” diseases are something of a misnomer: about 30 million Americans, half of them children, have a rare disease – and 90% have no approved treatments at all. The need…
The balance of healthcare innovation lies in developing new treatments, while also ensuring that everyone has access and nobody is left behind. At Koneksa, our team has been busy pushing...
Read More
Koneksa recently participated in two milestone gatherings in the digital health community. Let’s talk about what they were and why they matter! The first was the first meeting of the…
Another year has flown by! We’re always looking ahead, but it’s also good to look back. In 2022, our team has grown, changed, and affected clinical research in many ways….
At the recent CNS Summit – an annual gathering of R&D life science leaders that has taken place since 2009 – Koneksa was proud to sit down with some of…
Using data from digital health technologies is making it possible to measure the performance of investigational treatments more rapidly, completely, and accurately than ever before. What’s a digital biomarker?Biomarkers are,…
This recent conference in Zürich, sponsored by the Foundation for the National Institutes of Health (FNIH), the Wellcome Trust (UK) and the Swiss Federal Institute of Technology in Zürich (ETH…
While the breakneck pace of technological innovation has affected nearly every facet of modern life, the opportunities it has created in clinical research have been game-changing. This has been particularly…
When our Chief Scientific Officer, Dr. Elena Izmailova, founded what was then the “Women of Koneksa” group, our company had fewer than 30 people, most of whom were men, and…
At the recent Digital Biomarkers and Clinical Measures in Neurology meeting, Koneksa was honored to speak on the importance of digital biomarkers to research into central nervous system (CNS) conditions,…
If you’re reading this, it’s overwhelmingly likely that you have a smartphone, and possibly a fitness tracker. Digital Health Technologies (DHTs) like these can help us learn more about our…
Koneksa CMO John Wagner, MD, Ph.D. discussed the benefits and challenges of using biomarkers and translational science in clinical development programs at an FDA workshop hosted by the Duke-Margolis Center…
Koneksa’s unique expertise in designing, developing, and deploying digital health technology (DHT)-enabled biomarkers in clinical trials, and our experience analyzing the corresponding data, can provide value to your product’s journey….
